Fat loss
CagriSema
Once-weekly fixed-dose combination of Cagrilintide and Semaglutide. The leading 'next-generation' obesity treatment in Phase 3, delivering roughly 20% weight loss in late trials.
€189.99per vial
Choose an option
1
- Pay with Bitcoin
- Discreet shipping within Germany
- Purity-guaranteed batches
- 14-day refund period if unsatisfied
Delivery & guarantee
Orders typically arrive within 3 weeks.
If your delivery arrives late, you'll receive a discount on your next order.
About
CagriSema pairs Novo Nordisk's two molecules at matched doses in a single weekly injection. Amylin and GLP-1 operate through non-overlapping satiety pathways, so the effect adds rather than redundantly stacks on top of GLP-1 alone.
Read the full research guideWhy people choose it
- Roughly 20 to 23% body-weight reduction at full dose over 68 weeks in REDEFINE 1
- Better GI tolerability at matched weight loss than escalated Semaglutide monotherapy
- Single weekly injection. Both components in one syringe
- Strong glycaemic control for users with concurrent type 2 diabetes
At a glance
- Experience level
- Advanced
- Administration
- Subcutaneous
Sold for laboratory research only. Not for human consumption. No therapeutic claims are made.
Sign in to view this product
CagriSema
Log in or create a free account to see full details and prices.
Don't have an account? Sign up